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Abstract
Loss of basement membrane (BM) integrity is typically associated with cancer. Nidogen-1 is an essential
component of the BM. Nidogen-1 is a substrate for cathepsin-S (CatS) which is released into the tumor
microenvironment. Measuring nidogen-1 degraded by CatS may therefore have biomarker potential in cancer. The
aim of this study was to investigate if CatS-degraded nidogen-1 was detectable in serum and a possible biomarker
for cancer, a pathology associated with disruption of the BM. A competitive enzyme-linked immunosorbent assay
(NIC) was developed with a monoclonal mouse antibody specific for a CatS cleavage site on human nidogen-1.
Dilution and spiking recovery, inter- and intravariation, as well as accuracy were evaluated. Serum levels were
evaluated in patients with breast cancer, small cell lung cancer (SCLC), and non-SCLC (NSCLC) and in healthy
controls. The results indicated that the NIC assay was specific for nidogen-1 cleaved by CatS. Inter- and intraassay
variations were 9% and 14%, respectively. NIC was elevated in NSCLC as compared to healthy controls (P b .001),
breast cancer (P b .01), and SCLC (P b .5). The diagnostic power (area under the receiver operating characteristics)
of NIC for NSCLC as compared to all other samples combined was 0.83 (95% confidence interval: 0.71-0.95),
P b .0001. In conclusion, nidogen-1 degraded by CatS can be quantified in serum by the NIC assay. The current
data strongly suggest that cathepsin-S degradation of nidogen-1 is strongly associated with NSCLC, which needs
validation in larger clinical cohorts.
Neoplasia (2017) 19, 271–278
Introduction
Amajor component of the tumor microenvironment is the extracellular
matrix (ECM).Disruption of the healthy tissue homeostasis and altered
turnover of the ECM are hallmarks of cancer and lead to progression of
the disease [1]. The basement membrane (BM) is a specialized layer of
ECM that underlies and surrounds epithelial cells, endothelial cells, and
mesenchymal cells and hereby is essential for embryonic development as
well as for maintaining tissue architecture and cellular polarization [2].
The BM also serves as a barrier for cell invasion, and breaching of the
BM and loss of BM integrity have been associated with an invasive
phenotype in cancer [3]. Thus, it is important to develop cancer
biomarkers associated with BM disruptions.
Nidogens are highly conserved proteins that are found in almost all
BMs [4]. Two different nidogens exist: nidogen-1 (entactin) and
nidogen-2. Nidogen-1 is the most widely expressed and comprises
three globular domains (G1, G2, and G3) connected by two
rod-shaped domains. Nidogen-1 serves as the linker between other
BM proteins, namely, collagen type IV, perlecan, and laminin [5].
Hereby, nidogen-1 plays a key role in the BM assembly and
stabilization [6], as is also evident by the lung and heart abnormalities
and perinatal death observed in nidogen-deficient mice as a direct
result of BM changes [7].
The interaction between nidogen-1 and other BM components has
been studied both in vitro and in vivo [8–10]. Type IV collagen and
perlecan bind to the G2 domain, and laminin binds to the G3
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domain [5]. Especially the binding between nidogen-1 and laminin
has been extensively studied [11–13]. Inhibition of this interaction
results in defects in BM formation in both organ and co-culture
systems [14–17]. Moreover, it has been shown that mice lacking
nidogen-1 have impaired wound healing [18].
Nidogen-1 is a substrate for cathepsin-S (CatS), but not cathepsin
B, H, K, and L [19]. Degradation of nidogen-1 by CatS results in
impaired binding between nidogen-1 and type IV collagen, laminin,
and perlecan and hereby affects the properties of the BM [19].
Cathepsins are thought to play an important role in cancer and have
functional roles in growth, angiogenesis, invasion, and metastasis of
tumor cells [20]. In general, cathepsins become active at acidic pH
such as in lysosomes [21] but are inactive at neutral pH such as in the
extracellular environment [22]. CatS, however, retains most of its
activity at neutral pH [23].
CatS is produced in both tumor cells and tumor-associated
macrophages (TAMs) [24], and CatS has been shown to promote
growth, angiogenesis, migration, invasion, and mestatasis in different
cancer types [24–27]. As nidogen-1 is a key protein of the BM and
CatS is an important protein for cancer biology, this interaction may
provide a biological set-point, with increased accuracy for cancer and
biomarker development.
We hypothesized that nidogen-1 degraded by CatS may have
biomarker potential in cancer as it may reflect loss of BM integrity, a
phenomenon which is typically associated with procancer events and
an invasive phenotype. The aim of this study was to enable
noninvasive assessment of CatS-degraded nidogen-1 and investigate
this as a biomarker for cancer.
Material and Methods
Selection of Peptides
The following three main CatS cleavage-sites (↓) on nidogen-1 were
previously identified by N-terminal sequencing and published by Sage
et al. [19]: 1) NH3-…LLPL
459↓APVG…, located within the central part
of the G2 domain; 2) NH3-…HERE
693↓QHILG…, located in the
thyroglobulin-like (Tg) domain adjacent to the G3 domain; and 3)
NH3-…RQDL
859↓QGSPE…, located at the N-terminal part of the G3
domain. We chose to target the second cleavage site located outside the
globular domains in the direction toward the N-terminus, i.e. NH3-…
HERE693↓. We chose to name this target NIC.
To generate an antibody specific for the selected CatS cleavage site
on nidogen-1, a sequence of 11 amino acids just adjacent to the
cleavage site was chosen as the target: NH3-… VEKTRCQHERE↓.
This amino acid sequence was used to design the selection peptide.
The sequence was blasted for homology to other human proteins
using NPS@: Network Protein Sequence Analysis with the
UniprotKB/Swiss-prot database [28] and found to be unique to
human nidogen-1.
All synthetic peptides (Table 1) were purchased from the American
Peptide Company, Vista, CA. A biotinylated screening peptide
(Biot in-VEKTRCQHERE) was inc luded to coat the
streptavidin-coated plates. To test for specificity of the antibody, a
truncated selection peptide (EVEKTRCQHER) missing the one
amino acid closest to the cleavage site and an elongated selection
peptide (VEKTRCQHEREH), with an additional amino acid added
C-terminally to the cleavage site, as well as a nonsense selection
peptide (APVGGIIGWM) and a nonsense biotinylated screening
peptide (Biotin-APVGGIIGWM), were included in the assay
development. The latter two correspond to the cleavage site located
within the central part of the G2 domain (↓APVG…). The
immunogenic peptide (KLH-VEKTRCQHERE) was generated by
covalently cross-linking the selection peptide to Keyhole Limpet
Hemocyanin (KLH) carrier protein using succinimidyl
4-(N-maleimidomethyl)cyclohexane-1-carboxylate (Thermo Scientif-
ic, Waltham, MA; cat. #22336).
Antibody Development: Immunization and Hybridoma Screening
Six-week-old BALB/c mice (n = 6) were immunized subcutane-
ously with 200 μl of emulsified antigen and 50 μg of the
immunogenic peptide (KLH-VEKTRQHERE) using Freund's
incomplete adjuvant (Sigma-Aldrich, St. Louis, MO). Immunizations
were repeated every second week, and blood samples were collected
from the second immunization until stable serum antibody titer levels
were reached. The mice with the highest antibody titer rested for a
month and were then boosted intravenously with 50 μg immuno-
genic peptide in 100 μl of 0.9% sodium chloride solution. Three days
later, the spleen was isolated for cell fusion. The fusion procedure was
performed as described elsewhere [29]. Briefly, mouse spleen cells
were fused with SP2/0 myeloma cells to produce hybridoma cells.
The hybridoma cells were cloned in culture dishes, and limited
dilution was used to secure monoclonal growth. Native reactivity and
peptide binding of the monoclonal antibodies were evaluated by
displacement using human serum samples and the selection peptide
(VEKTRCQHERE) in a preliminary enzyme-linked immunosorbent
assay (ELISA) using 10 ng/ml of screening peptide on a
streptavidin-coated microtiter plate (Roche, Basel, Switzerland; cat.
#11940279) and the supernatant from the growing monoclonal
hybridoma cells (containing the antibodies). The clones with best
reactivity were purified using protein-G-columns according to the
manufacturer's instructions (GE Healthcare Life Sciences, Little
Chalfont, UK; cat. #17–0404-01). Two hybridoma clones qualified
to a screening for their ability to react competitively only with the
selection peptide (VEKTRCQHERE) and not with the truncated
(EVEKTRCQHER), elongated (VEKTRCQHEREH), and non-
sense (APVGGIIGWM) selection peptides. One hybridoma clone
was chosen for further assay development. Optimal incubation buffer,
time, and temperature, as well the optimal concentrations of antibody
and screening peptide, were determined from checkerboard analysis.
Proteolysis of Nidogen-1 In Vitro
Human recombinant (hr-) nidogen-1 (R&D Systems, Minneapolis,
MN; cat. #2570-ND) was dissolved in CatS buffer [100 mM
NaH2PO4(H2O)2, 2 mM DTT, 0.01% Brij-35, pH 7.4] or matrix
metalloproteinase (MMP) buffer (50 mM Tris, 150 mMNaCl, 10 mM
CaCl2, 10 μMZnCl, pH 7.5) to a final concentration of 125 μg/ml. The
nidogen-1 solutions were incubated at 37°C for 1 and 24 hours with or
without the addition of hr.-cathepsin S (Calbiochem, Whitehouse
Table 1. Amino Acid Sequence of the Synthetic Peptides Used for Antibody Production and Assay
Validation
Selection peptide VEKTRCQHERE
Immunogenic peptide KLH-VEKTRCQHERE
Screening peptide Biotin-VEKTRCQHERE
Truncated selection peptide EVEKTRCQHER
Elongated selection peptide VEKTRCQHEREH
Nonsense selection peptide APVGGIIGWM
Nonsense screening peptide Biotin-APVGGIIGWM
272 Nidogen-1 Degraded by CatS is Associated w/ NSCLC Willumsen et al. Neoplasia Vol. 19, No. 4, 2017
Station, NJ; cat. #219343), hr.-MMP-1 (R&D Systems, cat. #901-MP),
hr.-MMP-7 (R&D Systems, cat. #907-MP), or hr.-MMP-9 (R&D
Systems, cat. #911-MP) in final concentrations of 1.25 μg/ml, resulting
in an enzyme-to-protein ratio of 1:100. The chosen MMPs had
previously been shown to degrade nidogen-1 [11,30]. Enzymatic activity
tests were performed in parallel with the actual cleavage of nidogen-1. The
reaction was stopped by adding E-64 or EDTA (final concentration of 1
μM) to CatS and MMP solutions, respectively. CatS and MMP buffer
with relevant proteases were included as controls. The experiment was
repeated twice. Samples were stored at −80°C until analysis. The cleavage
of nidogen-1 was confirmed by silver staining according to the
manufacturer's instructions (SilverXpress, Invitrogen, cat. #LC6100)
(Supplementary Figure 1A), and a Western blot was performed to
investigate if the CatS-generated fragments were of expected sizes
(Supplementary Figure 1B).
NIC Assay Protocol
The competitive ELISA procedure was as follows: a 96-well
streptavidin-coated microtiter plate was coated with 2.5 ng/ml of
screening peptide (Biotin-VEKTRCQHERE) dissolved in assay
buffer (50 mM Tris-BTB, 8 g/l NaCl, pH 8.0). The plate was
incubated for 30 minutes at 20°C in darkness and was subsequently
washed five times in washing buffer (20 mM Tris, 50 mM NaCl, pH
7.2). Then, 20 μl of selection peptide (VEKTRCQHERE) or sample
(e.g., serum) was added to appropriate wells. This was followed by
immediately adding 100 μl of monoclonal antibody dissolved in assay
buffer to a concentration of 20 ng/ml. The plate was incubated for 3
hours at 20°C followed by ×5 wash in washing buffer. Then, 100 μl of
goat anti-mouse POD-conjugated IgG antibody (Thermo Scientific,
Waltham, MA; cat. #31437) diluted 1:6000 in assay buffer (final
concentration of 130 ng/ml) was added to each well. The plate was
incubated for 1 hour at 20°C followed by five washes in washing
buffer. Next, 100 μl of tetramethylbenzinidine (Kem-En-Tec,
Taastrup, Denmark; cat. #438OH) was added; the plate was
incubated for 15 minutes at 20°C, and 100 μl of stopping solution
(1% H2SO4) was added. All incubation steps were performed while
the plate was shaking with 300 rpm. Finally, the optical density was
measured in a VersaMax ELISA microplate reader at 450 nm with
650 nm as reference. A four-parametric mathematical fit model was
used to plot a calibration curve. Data were analyzed using the
SoftMax Pro v.6.3 software.
Technical Evaluation of the NIC ELISA
The lower limit of detection (LLOD) was determined from 21
measurements of the zero sample (assay buffer) and was calculated as
the mean + 3 standard deviations. The upper limit of detection
(ULOD) was determined from 10 independent runs of the highest
selection peptide concentration employed in the standard curve and
calculated as the mean back-calibration concentration + 3 standard
deviations. The lower limit of quantification (LLOQ) was calculated
as the highest NIC levels quantifiable in serum with a coefficient of
variation below 30% reproduced from three independent runs of
serum samples diluted stepwise. The intraassay variation was
calculated as the mean coefficient of variance (CV %) within plates,
and the interassay variation was calculated as the mean CV %
between plates. The inter- and intraassay variations were determined
by 10 independent runs of 8 quality control samples and 2 internal
controls covering the detection range (LLOD-ULOD), with each run
consisting of double determinations of the samples. The eight samples
included two human serum samples, two animal serum samples spiked
with the selection peptide, and four pools of human serum samples spiked
with the selection peptide. Two-fold dilutions of human serumandplasma
EDTA samples were used to calculate linearity as a percentage of dilution
recovery of the undiluted sample. Accuracy was determined by spiking
human serum and plasma EDTA samples with two-fold dilutions of the
selection peptide and calculating the percentage spiking recovery using the
expected concentration (serum and peptide combined) as reference. The
effect of repeated freezing and thawing of the samples was determined for
three human serum and plasma EDTA samples in four freeze/thaw cycles.
The freeze-thaw recovery was calculated with the first cycle as reference.
Analyte stability was determined for three human serum and plasma
EDTA samples after 24 hours of storage at either 4°C or 20°C. Recovery
was calculated with samples stored at −20°C as reference. Interference was
determined by adding a low/high content of hemoglobin (0.155/0.310
mM), lipemia/lipids (4.83/10.98 mM), and biotin (30/90 ng/ml) to a
serum sample of known concentration. Recovery percentage was
calculated with the normal serum sample as reference.
Patient Samples
Serum samples consisted of two cohorts. An overview is given inTable 2.
Appropriate Institutional Review Board/Independent Ethical Committee
approved sample collection, and all the patients filed informed consent.
The first cohort was acquired from the commercial vendor Proteogenex
(Culver City, CA). The second cohort was a combination of cancer
patient samples acquired from the commercial vendor Asterand (Detroit,
MI) and healthy control samples obtained from another study population
(reg. no. KA99070gm). According to Danish law, it is not required to get
additional ethical approval when measuring biomarkers in previously
collected samples. All investigations were carried out in accordance with
the Helsinki Declaration.
Statistical Analysis
Serum levels of NIC were compared by one-way analysis of variance
(ANOVA) adjusted formultiple comparisonswithHolm-Sidak's test. The
area under the receiver operating characteristics (AUROC) curves was used
to assess the diagnostics power of NIC. Data were considered statistically
significant when P b .05. GraphPad Prism v6.05 andMedCalc Statistical
Software v14.8.1 were used to perform statistical analysis.
Results
Specificity of the NIC Assay
The specificity of the competitiveNICELISAwas evaluated by assessing
the percentage of inhibition induced by the selection peptide (VEKTRCQ-
HERE) as compared to an elongated selection peptide (VEKTRCQ-
HEREH), a truncated selection peptide (EVEKTRCQHER), a nonsense
Table 2. Patient Characteristics
Study Cohort Size Age Gender Tumor Stage
#1 n Median, Range Females I II III IV
Controls 8 55, 44-65 6 - - - -
Breast cancer 8 55, 34-62 8 - 3 5 -
NSCLC 8 62, 47-77 1 1 2 3 2
#2 n Median, Range Females I II III IV
Controls 43 72, 60-82 43 - - - -
Breast cancer 13 56, 43-69 12 - 11 2 -
NSCLC 12 58, 47-80 3 5 3 4 -
SCLC 8 57, 46-82 2 2 1 4 1
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selection peptide (APVGGIIGWM), and a nonsense screening peptide
(Biotin-APVGGIIGWM) (the latter two correspond to the cleavage site
locatedwithin the central part of theG2 domain on nidogen-1). Results are
shown in Figure 1A. The selection peptide clearly inhibited the signal in a
dose-dependent manner, whereas the signal was only slightly inhibited by
the truncated, elongated, and nonsense peptides at the highest
concentrations. No reactivity was detected toward the nonsense screening
peptide. In addition, the levels of NIC generated by incubating nidogen-1
with CatS and various MMPs were investigated. As shown in Figure 1B,
CatS generated NIC in a time-dependent manner (10.6 nM and 16.0 nM
at 1 and 24 hours of incubation, respectively). Approximately five-fold
higher levels ofNICwere detected after incubating nidogen-1withCatS for
24 hours. In contrast, no NIC was generated either without proteases
(below LLOD of 3.1 nM)or when incubating with MMP-1, MMP-7, or
MMP-9 (ranging from below LLOD of 3.1 nM to 3.5 nM). Altogether,
this indicates that the antibody is specific and that the assay accurately
measures nidogen-1 cleaved by CatS at amino acid position 693.
Technical Evaluation of the NIC Assay
The overall technical performance of the NIC assay is listed in
Table 3. The assay had an LLOD of 3.1 nM and a ULOD of
260 nM. The LLOQ was 3.2 nM. Intraassay variation was 9% and
the interassay variation was 14%, below the acceptance level of 10%
and 15%, respectively. All analyte recoveries were accepted if within
100 ± 20%. The dilution recovery was 104% and 92% for serum
and plasma EDTA, respectively, indicating good linearity when
diluting the samples. Spiking recovery for the standard peptide was
also acceptable in serum (91%) and plasma EDTA (94%), indicating
that these sample matrices do not affect assay response. The analyte
was recovered in both serum and plasma EDTA after four freeze-thaw
Figure 1. Specificity of the NIC assay. (A) The percentage of inhibition at given concentrations in the competitive NIC-2 ELISA tested with the
selection peptide (VEKTRCQHERE), an elongated selection peptide (VEKTRCQHEREH), a truncated selection peptide (EVEKTRCQHER), a
nonsense selection peptide (APVGGIIGWM), and a nonsense screening peptide (Biotin-APVGGIIGWM). %B/B0: B equals the OD at × nM
peptide and B0 equals the OD at 0 nM peptide. (B) NIC levels measured after cleavage of human recombinant nidogen-1 (Nid-1) with CatS, and
MMP-1, -7, and -9. Values below the LLOD were assigned the LLOD. *Representative of MMP-1, -7, and -9.
Table 3. Technical Validation of the NIC Assay
Technical Validation Step Results
Detection range (LLOD-ULOD) 3.1-260 nM
LLOQ 3.2 nM
Intraassay variation 9%
Interassay variation 14%
Dilution recovery in serum 104% (80-115%)
Dilution recovery in plasma EDTA 92% (81-100%)
Spiking recovery in serum 91% (83-105%)
Spiking recovery in plasma EDTA 94% (80-102%)
Freeze-thaw recovery in serum 95% (89-101%)
Freeze-thaw recovery in plasma EDTA 85% (78-101%)
Analyte stability serum 24 h, 4°C/20°C 88% (80-94%)/82% (71-87%)
Analyte stability plasma EDTA 24 h, 4°C/20°C 90% (86-94%)/98% (95-105%)
Interference biotin, low/high 98%/118%
Interference lipemia, low/high 93%/81%
Interference hemoglobin, low/high 105%/101%
Percentages are reported as mean with range shown in brackets.
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cycles with 95% and 85% recoveries, respectively. The analyte was
also recovered after storage at 4°C and 20°C for 24 hours, resulting in
88% and 82% recoveries for serum and 90% and 98% recoveries for
plasma EDTA at 4°C and 20°C, respectively. Together, this indicates
that the analyte is relatively stable. No interference was detected from
either low or high contents of biotin, lipids (lipemia), or hemoglobin,
with recoveries ranging from 81% to 105%.
Evaluation of NIC Levels in Serum from Patients with Lung
Cancer, Patients with Breast Cancer, and Healthy Controls
NIC levels were measured in serum from two different patient
cohorts. As shown in Figure 2A, NIC was significantly elevated
(P N .05) in serum from NSCLC patients as compared to healthy
controls and breast cancer patients. Median NIC in the NSCLC
patients was 20 nM, ranging from 13.1 to 51.1 nM. Median NIC in
the breast cancer patients was 13.3 nM, ranging from 6.9 to 17.3 nM,
and median NIC in the healthy controls was 12.4 nM, ranging from
8.9 to 14.4 nM. As shown in Figure 2B, NIC was significantly
elevated in serum from NSCLC patients as compared to healthy
controls (P b .001), breast cancer patients (P b .01), and patients
with SCLC (P b .05). In this cohort, median NIC in the NSCLC
patients was 13.4 nM, ranging from 7.6 to 22.1 nM. Median NIC in
the SCLC patients was 10.4 nM, ranging from 7.6 to 13.7 nM;
median NIC in the breast cancer patients was 9.8 nM, ranging from
3.3 to 16.2 nM; and median NIC in the healthy controls was 9.7 nM,
ranging from 4.0 to 15.1 nM.
NIC levels were also assessed according to tumor stage, an
important clinical parameter in cancer. Results are shown in Figure 3
for all cancers combined. In detail, all stages of disease had elevated
levels of NIC as compared to the healthy controls, whereas no
difference could be detected between stages. This indicates that NIC
is generated independent of tumor stage.
To analyze the diagnostic power of NIC with respect to NSCLC,
both cohorts were pooled and grouped in “NSCLC” versus“all
others,” and the AUROC was calculated. The AUROC was 0.83
(95% confidence intervals: 0.71-0.95), P b .0001. The ROC curve,
as well as the sensitivity and specificity at a preliminary estimated
optimal cutoff value, is shown in Figure 4. These findings indicate
that NIC is able to separate NSCLC patients from the other subjects
combined. Altogether, the present findings suggest that NIC may be
highly associated with NSCLC.
Discussion
In the present study, we describe the development and validation of a
robust competitive ELISA that enables noninvasive measurements of
fragments of nidogen-1 degraded specifically by CatS (NIC).
Moreover, to our knowledge, this is the first study to show that
nidogen-1 degraded specifically by CatS may have biomarker
potential for NSCLC.
CatS cleavage of nidogen-1 resulted in a specific fragment containing a
neo-epitope with the amino acid composition VEKTRCQHERE (the
NIC domain). Hereby, we were able to verify the findings by Sage et al.
showing that nidogen-1 is cleaved by CatS at amino acid position 693
(NH3-…HERE
693) which is located in the thyroglobulin-like (Tg)
domain adjacent to the G3 domain [19].
The elevated NIC levels found in serum from patients with
NSCLC as compared to patients with breast cancer, patients with
SCLC, and healthy controls suggest that NSCLC patients have
increased CatS-mediated degradation of nidogen-1. This was further
backed by the diagnostic accuracy of NIC (AUROC 0.83) for
NSCLC when compared to all other subjects. In detail, for NSCLC,
the average NIC levels were slightly lower in cohort 2 compared to
cohort 1 (Figure 2). This, together with the relatively large variation
within each group of patients, suggests however that NIC may not
serve as a diagnostic tool for lung cancer. Instead, NIC levels may be
indicative of a specific pathological event in a patient's tumor, and this
Figure 2. Evaluation of NIC in serum from two study cohorts. (A)
Proteogenex samples; (B) Asterand samples. Box and whiskers
show data from minimum to maximum. Data were compared by
one-way ANOVA adjusted for multiple comparisons. Values below
the LLOQ were assigned the LLOQ (n = 1, breast cancer, B).
*P b .05, **P b .01, ***P b .001.
Figure 3. Evaluation of NIC in serum according to tumor stage.
Samples were pooled according to tumor stage. Data are
presented as scatter plots with each cancer type identifiable.
Data were compared to healthy controls by one-way ANOVA
adjusted for multiple comparisons. ***P b .001, ****P b .0001.
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pathological event seems to bemore associated withNSCLC as compared
to the other cancer types analyzed. One would expect the amount of BM
in the given tumor type to be a limiting factor, and whether the NSCLC
cancer subtype has more BM (nidogen-1) compared to the other types of
cancer tested here remains to be established.
Intuitively, one would expect NIC, by reflecting altered BM
homeostasis, to be highly associated with an invasive phenotype and
potential for metastasizing. As NIC levels were elevated in all stages of
disease especially in NSCLC, this indicates that CatS degradation of
nidogen-1 is ongoing in both early and late stages of disease
independent of tumor stage and that NIC may be applied in the early
onset of disease. In this context, it is important to get a deeper
understanding of the role of CatS in relation to tumor-associated
events. CatS has been associated with different cancer types and
protumorigenic events [24–27]. However, the exact mechanisms
leading to increased expression of cathepsins in tumors have not been
investigated in detail [20].
The NIC domain was specifically generated by CatS and not by
MMPs that had previously been shown to degrade nidogen-1 [11,30].
This is important because different nidogen-1 fragments may reflect
different (patho)physiological events, i.e., nidogen-1 degraded by CatS
may reflect different disease activity patterns as compared to, for instance,
nidogen-1 degraded by an MMP [31]. The two other described CatS
cleavage sites, which are located within the G2 and G3 domains on
nidogen-1, are essential for the tertiary assembly of the BM [5,8].
Whether cleavage at the NIC domain is associated with similar or distinct
(patho)physiological features remains to be established.
CatS has been shown to be released from TAMs [24], and it has
been shown that, when co-culturing lung cancer cell lines with TAMs
isolated from NSCLC patients, cell invasion was increased and
associated with an upregulation of the expression of CatS in the
cancer cells [32]. Moreover, it has been shown that CatS through its
ECM-degrading properties affects angiogenesis [33]. Circulating
plasma levels of nidogen-1 have been detected in ovarian cancer,
especially at the advanced stage of disease [27]. Here, nidogen-1 levels
were measured using a sandwich ELISA developed with commercially
available antibodies from R&D Systems (cat. #DY2570); however,
the exact epitopes were unknown. Thus, in contrast to samples
measured with the NIC assay, it remains to be established how
nidogen-1 ended up in circulation from these ovarian cancer patients.
In fact, a complex network of proteolytic enzymes is involved in
tumor progression [34] and should be considered when evaluating the
impact of circulating fragments of nidogen-1. Nonetheless, our data
indicate that CatS is definitely involved in cleavage of nidogen-1 and
may be particularly associated with NSCLC. Still, in addition to the
tissue of origin, the degree of angiogenesis and invasion with
associated dynamic alterations in BM remodeling from both the
desmoplastic reaction and altered proteolytic activity may be highly
contributing to the differences observed in the patients.
It has been shown that nidogen-1 can regulate specific gene expression
in mammary epithelial cells [35]. When the expression of β-casein was
investigated as a function of nidogen quality/composition, a fragment of
nidogen containing the laminin-1 binding domain but lacking the type
IV collagen binding domain was able to reduce the expression of β-casein.
In contrast, a fragment of nidogen containing the type IV collagen
binding domain but lacking the laminin-111 binding domain was not.
These findings both suggest that nidogen enhances the effect of
laminin-111 binding to its receptors, which in turns supports mammary
gland differentiation and associated gene expression. This is similar to
observations described by Weaver et al. showing that it is possible to
repress the tumorigenic phenotype of breast cancer by modulating the
ECMand its receptors [36]. Together, these findings suggests that specific
(not all) nidogen-1 fragments may affect the cell-BM interaction and
hereby possibly contribute to tumorigenesis by affecting cell phenotype.
Thus, hypothetically, specific fragment of nidogen-1, such as NIC, may
reflect particular protumorigenic events.
Concerning the efficacy of anticancer drugs, ECM-modifying
drugs are currently investigated as possible interventions for
modulating the tumor microenvironment and obtain tumor
shrinkage or more efficient delivery of chemotherapeutic drugs and
targeted therapies. Interestingly, it has been shown that
antibody-mediated blockage of CatS enhances the efficacy of
chemotherapy [37]. Moreover, this antibody has been suggested as
a direct strategy for the treatment of solid tumors [38]. Potentially,
the NIC assay could be used for predicting which patients are most
likely to benefit from such treatment or for monitoring early efficacy
of treatment. Further studies are needed to investigate this, and the
current study provides the tool for such investigations.
An important parameter of the NIC assay is related to robustness,
i.e., technical and analytical evaluation. Technical evaluation of NIC
included the establishment of detection range, sensitivity, inter- and
intraassay variation, linearity/precision (dilution recovery), analyte
stability, and interference, which all were within acceptable limits.
Analytical evaluation of the NIC assay refers to the specificity of the
assay and to whether the assay detects the analyte it was designed to
detect in serum/plasma EDTA. The specificity was evaluated by
displacement analysis (Figure 1A) and by testing reactivity toward
intact and cleaved nidogen-1 (Figure 1B). Accuracy was evaluated by
spiking the analyte into the relevant matrices (serum and plasma
EDTA) and calculating the percentage recovery (also within
acceptable limits). Thus, the NIC assay was technically and
analytically robust, indicating that the assay is specific and able to
perform accurately over a period of time.
The present study is limited by relatively small population sizes and
the cross-sectional designs when evaluating NIC in relation to cancer.
Figure 4. ROC analysis evaluating the ability of NIC to separate
NSCLC from all other samples included in this study combined
(breast cancer, SCLC, and healthy controls). AUC, area under the
ROC curve.
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Moreover, clinical information was limited, not allowing for any
correlation analysis between the pathophysiology of individual
patients, or particular tumor phenotype, to the measured NIC levels.
In addition, gender could be a confounding factor, as the controls
were primarily female while the vast proportion of the NSCLC
samples were from males. However, in opposition to this, a significant
difference in NIC levels was also detected between more
gender-matched samples of different tumor types (e.g., NSCLC
versus SCLC). Larger longitudinal studies are necessary to validate the
present findings and to investigate any potential diagnostic and
prognostic applicability of NIC. Moreover, to get a better
understanding of biological relevance of NIC, it would be highly
relevant to correlate to other BM degradation products associated
with specific pathological events.
Conclusion
In conclusion, CatS-degraded nidogen-1 can be quantified in serum
by the technically robust NIC assay. NIC levels were elevated in
NSCLC patients as compared to breast cancer patients, SCLC
patients, and healthy controls. If validated in larger clinical studies,
the NIC assay may serve as a noninvasive biomarker for cancer and
provide important insight into tumor biology.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2017.01.008.
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